/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Viracta Therapeutics (VIRX) generated about n/a in revenue and -$43 million in net income over the trailing twelve months, growing at roughly -47.7% a year. Figures are from SEC filings; this is analysis, not investment advice.
Viracta Therapeutics reported about -$43 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Viracta Therapeutics's revenue has compounded at roughly -47.7% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside VIRX's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 13 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.
Fiscal year ends Dec.